AbCellera Biologics (ABCL) Competitors $2.36 -0.06 (-2.48%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.42%) As of 03/27/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABCL vs. MTSR, ACAD, MOR, RXRX, XENE, AMRX, HCM, CPRX, BHC, and NAMSShould you be buying AbCellera Biologics stock or one of its competitors? The main competitors of AbCellera Biologics include Metsera (MTSR), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), Recursion Pharmaceuticals (RXRX), Xenon Pharmaceuticals (XENE), Amneal Pharmaceuticals (AMRX), HUTCHMED (HCM), Catalyst Pharmaceuticals (CPRX), Bausch Health Companies (BHC), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. AbCellera Biologics vs. Metsera ACADIA Pharmaceuticals MorphoSys Recursion Pharmaceuticals Xenon Pharmaceuticals Amneal Pharmaceuticals HUTCHMED Catalyst Pharmaceuticals Bausch Health Companies NewAmsterdam Pharma Metsera (NASDAQ:MTSR) and AbCellera Biologics (NASDAQ:ABCL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Is MTSR or ABCL more profitable? Metsera has a net margin of 0.00% compared to AbCellera Biologics' net margin of -533.32%. Metsera's return on equity of 0.00% beat AbCellera Biologics' return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A AbCellera Biologics -533.32%-15.73%-12.22% Which has stronger valuation & earnings, MTSR or ABCL? Metsera has higher earnings, but lower revenue than AbCellera Biologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/AN/AN/AN/AAbCellera Biologics$28.83M24.39-$146.40M-$0.55-4.29 Do institutionals & insiders believe in MTSR or ABCL? 61.4% of AbCellera Biologics shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor MTSR or ABCL? In the previous week, Metsera had 5 more articles in the media than AbCellera Biologics. MarketBeat recorded 9 mentions for Metsera and 4 mentions for AbCellera Biologics. AbCellera Biologics' average media sentiment score of 1.02 beat Metsera's score of 1.01 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer MTSR or ABCL? AbCellera Biologics received 51 more outperform votes than Metsera when rated by MarketBeat users. However, 100.00% of users gave Metsera an outperform vote while only 75.34% of users gave AbCellera Biologics an outperform vote. CompanyUnderperformOutperformMetseraOutperform Votes4100.00% Underperform VotesNo VotesAbCellera BiologicsOutperform Votes5575.34% Underperform Votes1824.66% Do analysts recommend MTSR or ABCL? Metsera presently has a consensus target price of $47.00, suggesting a potential upside of 56.61%. AbCellera Biologics has a consensus target price of $7.00, suggesting a potential upside of 196.61%. Given AbCellera Biologics' higher possible upside, analysts clearly believe AbCellera Biologics is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 SummaryMetsera beats AbCellera Biologics on 7 of the 13 factors compared between the two stocks. Remove Ads Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABCL vs. The Competition Export to ExcelMetricAbCellera BiologicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$703.25M$6.91B$5.64B$8.06BDividend YieldN/A2.73%4.56%4.02%P/E Ratio-3.877.2023.1319.03Price / Sales24.39226.01383.8993.17Price / CashN/A65.6738.1634.64Price / Book0.596.476.944.33Net Income-$146.40M$141.90M$3.20B$247.06M7 Day Performance-0.84%-3.05%-2.30%-0.52%1 Month Performance-19.32%-4.63%3.10%-3.73%1 Year Performance-47.44%-8.61%11.22%1.74% AbCellera Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABCLAbCellera Biologics2.4628 of 5 stars$2.36-2.5%$7.00+196.6%-47.4%$703.25M$28.83M-3.87500Positive NewsMTSRMetseraN/A$28.81+14.3%$47.00+63.1%N/A$2.97BN/A0.0081Earnings ReportNews CoverageACADACADIA Pharmaceuticals4.1525 of 5 stars$17.27-1.3%$24.00+39.0%-5.5%$2.89B$957.80M22.18510MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730RXRXRecursion Pharmaceuticals2.2211 of 5 stars$6.85+7.8%$8.25+20.5%-41.3%$2.74B$58.49M-4.46400Gap DownXENEXenon Pharmaceuticals2.4877 of 5 stars$35.23-0.3%$57.38+62.9%-19.9%$2.69B$9.43M-12.48210AMRXAmneal Pharmaceuticals3.458 of 5 stars$8.68-0.8%$10.80+24.4%+35.1%$2.69B$2.79B-12.777,700Positive NewsHCMHUTCHMED1.6515 of 5 stars$15.22-3.0%$19.00+24.8%-9.4%$2.65B$610.81M0.001,988Gap DownCPRXCatalyst Pharmaceuticals4.8399 of 5 stars$21.77+3.6%$32.50+49.3%+52.7%$2.65B$491.73M18.4880BHCBausch Health Companies3.5511 of 5 stars$7.09-0.9%$7.42+4.7%-35.7%$2.60B$9.63B-58.9520,270Options VolumeNews CoverageNAMSNewAmsterdam Pharma2.1131 of 5 stars$23.40+0.1%$43.33+85.2%-1.3%$2.56B$45.56M-8.964Short Interest ↑High Trading Volume Remove Ads Related Companies and Tools Related Companies Metsera Competitors ACADIA Pharmaceuticals Competitors MorphoSys Competitors Recursion Pharmaceuticals Competitors Xenon Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors HUTCHMED Competitors Catalyst Pharmaceuticals Competitors Bausch Health Companies Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABCL) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ABCL Stock Free ABCL Stock Alerts